BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lees CW, Irving PM, Beaugerie L. COVID-19 and IBD drugs: should we change anything at the moment? Gut 2021;70:632-4. [PMID: 33214164 DOI: 10.1136/gutjnl-2020-323247] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Mucino-bermejo M. COVID-19 and the Gastrointestinal Tract. Gastroenterology Insights 2021;12:394-404. [DOI: 10.3390/gastroent12040038] [Reference Citation Analysis]
2 El Ouali S, Rubin DT, Cohen BL, Regueiro MD, Rieder F. Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic. Curr Opin Gastroenterol 2021;37:313-9. [PMID: 33859104 DOI: 10.1097/MOG.0000000000000741] [Reference Citation Analysis]
3 Meyer A, Semenzato L, Zureik M, Weill A, Carbonnel F, Dray-Spira R. Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study. Aliment Pharmacol Ther 2021;54:160-6. [PMID: 34110040 DOI: 10.1111/apt.16410] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Alrashed F, Battat R, Abdullah I, Charabaty A, Shehab M. Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis. BMJ Open Gastroenterol 2021;8:e000774. [PMID: 34725056 DOI: 10.1136/bmjgast-2021-000774] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
5 M’koma AE. Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview. Medicina 2022;58:567. [DOI: 10.3390/medicina58050567] [Reference Citation Analysis]
6 Din S, Gaya D, Kammermeier J, Lamb CA, Macdonald J, Moran G, Parkes G, Pollok R, Sebastian S, Segal J, Selinger C, Smith PJ, Steed H, Arnott ID. Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic. Frontline Gastroenterol 2022;13:77-81. [PMID: 34966535 DOI: 10.1136/flgastro-2021-101805] [Reference Citation Analysis]
7 Gilissen LPL, Heinen SGH, Rijpma-Jacobs L, Schoon E, Schreuder RM, Wensing AM, van der Ende-van Loon MCM, Bloemen JG, Stapelbroek JM, Stronkhorst A. Neither inflammatory bowel disease nor immunosuppressants are associated with an increased risk of severe COVID-19: an observational Dutch cohort study. Clin Exp Med 2021. [PMID: 34542781 DOI: 10.1007/s10238-021-00755-3] [Reference Citation Analysis]